BioNexus
Category: AI in Biotech / Drug Discovery
Korean AI biotech startup developing AI scientist agents that automate hypothesis generation and drug discovery through multi-agent collaboration. BioNexus was founded in 2024. The company is led by Kim Tae-hyung (김태형). Based in Suwon, Gyeonggi-do, South Korea. Team size: 11-50. Latest round: Seed. Key investors include Base Ventures (베이스벤처스), SMB Investment Partners (SMB투자파트너스).
- Founded
- 2024
- Headquarters
- Suwon, Gyeonggi-do, South Korea
- Team size
- 11-50
Value proposition
An AI-powered bio data platform that combines bio data intelligence with scientist agents to accelerate drug discovery — automating hypothesis generation, data analysis, validation, and experimental design across the entire research workflow.
Products and solutions
NexusScience (core engine structuring scientist reasoning/research process), NexusRAG (custom research search tool), Nexus Co-Scientist (multi-agent collaborative research platform generating and validating hypotheses), NexusDrugLab (drug & target analysis platform).
Unique value
Field-proven AI scientist agents (30+ research projects, 15 institutional partnerships) that mirror human research teams — multiple AI agents divide roles (search, hypothesis generation, review, evaluation) and collaborate to refine outputs, differentiating from global big-tech entrants through real-world validation experience.
Target customer
Biotech/pharma R&D organizations, research institutions, and healthcare data science teams seeking AI-driven drug discovery and research acceleration.
Industries served
Biotech / Drug Discovery, Bioinformatics, Healthcare Data Science, Life Sciences R&D
Technology advantage
LLM-based multi-agent system analyzing 500K+ literature & omics data; in-house capability spanning data construction, model development, and field validation; bioinformatics PhD-level researchers combined with AI/LLM engineers and drug development/clinical/omics experts.
How they differentiate
Differentiates through real-world field validation experience (30+ completed research projects, 15 institutional partnerships) versus global big-tech AI scientist entrants, and through a multi-agent collaboration architecture that mirrors human research team workflows.
Main competitors
Selkey AI (셀키에이아이), BioResearch AI (바이오리서치에이아이), SilicoPharm (실리코팜), 3BIGS (쓰리빅스), Aimble (에임블), NetTarget (넷타겟)
Key partnerships
Korea Basic Science Institute (한국기초과학지원연구원), National Primate Research Center (국가영장류센터), Korea Institute of Ocean Science & Technology (한국해양과학기술원), AI Anti-Aging Research Institute (AI역노화연구원), 15+ joint research institutions total.
Notable customers
Korea Basic Science Institute, National Primate Research Center, Korea Institute of Ocean Science & Technology, AI Anti-Aging Research Institute (15+ joint research institutions)
Major milestones
Founded Nov 2024, completed 30+ research projects, built 15+ institutional joint-research network, raised Seed funding from Base Ventures & SMB Investment Partners (Aug 2026).
Growth metrics
17 employees (June 2026); 30+ research projects completed; 15+ institutional partnerships; 500K+ literature & omics data analyzed.
Market positioning
Early-stage (Seed) Korean startup in the emerging AI scientist / AI drug discovery market, competing with both domestic bio-data AI startups and global big-tech AI scientist initiatives (e.g., Google DeepMind).
Geographic focus
South Korea (domestic research institutions), with plans to expand domestically and internationally.
About Kim Tae-hyung (김태형)
Ex-Theragen Bio (테라젠바이오) Division Head / Managing Director (~2024.07); ~20 years in bio big data analysis; participated in Korean human genome map and whale genome map projects; current member of National AI Strategy Committee, National Science & Technology Advisory Council, National Bio Innovation Committee.
Latest news about BioNexus
More AI in Biotech / Drug Discovery companies
Official website: https://bionexus.kr